Data Provided by Refinitiv. Minimum 15 minutes delayed.
–
Summary ToggleIntellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
